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Summary 
The International Pachyonychia Congenita Consortium (IPCC) is a group of physicians and 
scientists from around the world dedicated to developing therapies for pachyonychia congenita, 
a rare autosomal dominant skin disorder. The research presented at the 13th Annual Research 
Symposium of the IPCC, held on 10–11 May 2016, in Scottsdale, AZ, U.S.A., is reported here.  
 
 
 
 
The 13th Annual Research Symposium of the International Pachyonychia Congenita 
Consortium (IPCC) was held in Scottsdale, AZ, U.S.A. on 10–11 May 2016. The meeting was 
attended by about 40 physicians and scientists from around the world devoted to discussing 
progress and future studies towards developing therapies for pachyonychia congenita (PC), a 
rare autosomal dominant keratinizing skin disorder. Severe plantar pain, palmoplantar 
keratoderma including calluses with underlying blisters, and variable hypertrophic nail 
dystrophy are the main characteristics, often accompanied by oral leucokeratosis, cysts of 
various types, follicular hyperkeratosis, palmoplantar hyperhidrosis and sometimes natal 
teeth.1,2 PC is caused by a mutation in one of five keratin genes: KRT6A, KRT6B, KRT6C, 
KRT16 or KRT17.
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Day 1 morning session 
The first session, chaired by Laure Rittié (University of Michigan, Ann Arbor, MI, U.S.A.), 
opened with a presentation on ‘PC genetics’ (Frances Smith, PC Project) (all presentations are 
listed in Table S1; see Supporting Information). An update was given on patients enrolled in 
The International Pachyonychia Congenita Research Registry (IPCRR), established in 2004 to 
collect clinical and molecular data from patients with PC worldwide. It is readily accessible as 
patients can self-refer through the website or via a clinician referral. Within the IPCRR there are 
over 700 cases with genetically confirmed PC, and more than 100 different dominant mutations 
have been identified (no cases confirmed of recessive PC). To date, 51 cases within the IPCRR 
have been identified that do not have mutations in KRT6A, KRT6B, KRT6C, KRT16 or 
KRT17, but rather have mutations in other genes including GJB6, TRPV3, DSG1, DSP, 
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KRT9, FZD6 or AAGAB. While these cases are not PC, the findings provide a diagnosis to these 
individuals who have various known disorders distinct from PC, but with some similar features. 
Eli Sprecher (Tel Aviv Sourasky Medical Center, Tel Aviv, Israel) discussed ‘Genodermatoses 
and unusual modes of inheritance’. Using a number of different skin disorders as examples, 
including epidermolysis bullosa simplex, epidermolytic ichthyosis, familial tumoral calcinosis, 
autosomal recessive congenital ichthyosis and X-linked ichthyosis, he explained different 
modes of inheritance from monogenic and semidominant to polygenic, and the role of modifier 
genes. 
Pierre Coulombe (Johns Hopkins University, Baltimore, MD, U.S.A.) presented ‘Keratin 
mutation vs. pathogenesis in PC: challenges and opportunities’, giving an overview of keratins 
and the challenges in studying associated disorders. He discussed that although very similar in 
sequence homology, keratins 14, 16 and 17 have very different functions, as shown by the 
distinct null phenotypes in mouse models. The discussion on the complex keratin ecosystem of 
plantar epidermis was a great introduction for a later presentation by Michelle Kerns (Johns 
Hopkins University). She spoke about her very recently published work, ‘The role of oxidative 
stress and dysfunctional Nrf2 in PC-associated palmoplantar keratoderma’.4
Catherine Lu (Rockefeller University, NY, U.S.A.) reported on her recent studies, ‘Stem cells in 
the sweat glands: wound repair and regeneration’.
 She showed that 
oxidative stress and dysfunctional Nrf2 act as contributors to the pathogenesis of palmoplantar 
keratoderma. Keratin 16 is a regulator of Nrf2 activation, and pharmacological activation of 
Nrf2 or modulation of oxidative stress should be further explored as possible treatments for PC. 
5
Several talks throughout the meeting focused on plantar pain, the most debilitating symptom of 
PC (shared by 95% of patients; www.pachyonychia.org). The significant plantar pain endured 
by patients with PC and its effects on patients’ quality of life has been a major focus of the IPCC 
for several years. Great strides were reported at the PC meeting. To gain a better understanding 
of the type of pain that patients experience, the first pain research study for PC was started in 
2011, at a patient support meeting on 35 U.S. patients with mutations in KRT6A, KRT6B, 
KRT16 or KRT17. The study concluded that significant neuropathic pain was observed in 
patients with PC.
 She gave an introduction to murine sweat 
gland biology, demonstrating the use of mouse models to answer questions that cannot easily be 
done using human samples. Using the mouse model as a surrogate for human disease, she 
investigated keratin expression in mouse sweat glands and foot epidermis to address the 
question: ‘why mutations in PC keratins would cause hyperhidrosis?’. 
6 
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Silviu Brill (Pain Medicine Institute, Tel Aviv Medical Center, Israel) presented results from a 
second larger study conducted on 62 patients with PC with mutations in KRT6A or KRT16 (and 
45 matched controls). This study was carried out at three PC patient support meetings in 
2014–2015, held in Paris, France; Edinburgh, Scotland; and Newark, U.S.A. by the same group 
of pain specialists, led by Ruth Defrin (Tel Aviv University, Israel). The research questions 
were (i) are patients with PC experiencing neuropathic pain? and (ii) is there a difference in 
prevalence between the genotypes? A systematic quantitative controlled study was performed 
using conduction and pain modulation tests, as well as pain and quality-of-life questionnaires. 
Overall the study showed that there were sufficient signs, such as the association of PC with 
moderate-to-strong chronic pain and local mechanical hyperalgesia, to indicate the presence of 
peripheral neuropathic pain in these patients (manuscript in preparation). 
Andreas Berroth (TransDerm Inc., CA, U.S.A.) gave an update on his work studying ‘The role 
of microRNAs in PC’. He summarized his in vitro work in which he tested the effects of the 
microRNAs that were found to be differentially expressed in PC-involved vs. healthy skin on 
keratinocyte proliferation and differentiation. His early preliminary data were discussed in the 
context of the known pathophysiology of PC. 
The morning session closed with an enlightening talk from Dennis Roop (University of 
Colorado, CO, U.S.A.) on the exciting progress in his lab to develop ‘Stem cell therapies for 
EB’ (epidermolysis bullosa). His lab has developed a successful protocol for growing induced 
pluripotent stem (iPS) cells for therapeutic use, and is moving towards the clinical application 
of iPS cell-based therapy for patients with recessive dystrophic epidermolysis bullosa 
harbouring a particular COL7A1 mutation. Dr Roop concluded by discussing the new facility 
for performing the work, the Charles C. Gates Biomanufacturing Facility, at the University of 
Colorado. The audience wondered whether iPS cell therapy would be feasible in PC given that 
it is inherited in a dominant fashion. Although there were foreseeable obstacles that would need 
to be overcome, it was discussed that it was recently shown that mutation site-specific genome 
editing in iPS cells from dominant negative disorders (i.e. dominant dystrophic epidermolysis 
bullosa) was technically feasible.7
 
 The group thought the approach was thus worth taking into 
consideration. 
Day 1 afternoon session 
The afternoon session, chaired by Roger Kaspar (TransDerm Inc., Santa Cruz, CA, U.S.A.), 
began with a presentation by Jiang Chen (Stony Brook University, Stony Brook, NY, U.S.A.) 
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on ‘Cell to cell adhesion relative to blistering’. Dr Chen described the newly discovered role of 
RPGRIP1L in organizing desmosome assembly in keratinocytes. Disruption of the RPGRIP1L 
gene resulted in intraepidermal blistering in mice. Blocking of protein kinase C beta II, which is 
consistently upregulated in these animals, partially rescued the blistering phenotype thereby 
revealing a novel potential therapeutic approach for blistering diseases. 
Karen Wagner (University of California Davis, CA, U.S.A.) spoke about soluble epoxide 
hydrolase inhibitors in her presentation ‘Analgesia mediated by soluble epoxide hydrolase 
inhibition and epoxy fatty acid metabolites’. The current approaches to target this enzyme as a 
potential therapy to combat neuropathic pain were outlined. She showed how inhibition of 
soluble epoxide hydrolase eliminates inflammatory pain and can block neuropathic pain. 
Examples were shown to demonstrate the effectiveness of the enzyme in clinical conditions in 
animals, for example in laminitis, a severe inflammation of the hoof in horses that triggers 
neuropathic pain.8
Birgit Lane (Institute of Medical Biology, A*STAR, Singapore) gave an overview of the 
growth of skin research in Singapore with the development of the Skin Research Institute of 
Singapore, a collaboration between the Agency for Science, Technology and Research 
(A*STAR), the National Skin Center and Nanyang Technological University. She discussed 
ongoing studies in her own lab using cell models to study epidermolysis bullosa simplex and 
potential treatments. 
 She discussed how this therapy may be relevant for PC. 
Maria Morasso (National Institutes of Health, Bethesda, MD, U.S.A.) reported on her studies 
identifying single-nucleotide polymorphisms present in different hair keratins expressed in 
tooth enamel.9
Tycho Speaker (TransDerm Inc., Santa Cruz, CA, U.S.A.) spoke about a Flex-PAD soluble 
microneedle array system as an alternative to hypodermic injection to administer botulinum 
toxin. Botulinum toxin is being considered by the IPCC for a future clinical trial to reduce the 
painful keratoderma (see below). The strategy takes advantage of the ability of botulinum toxin 
type A to suppress eccrine sweat glands, inhibiting sweat production, potentially reducing 
plantar blistering and pain. Several small studies have shown that injection of botulinum toxin 
type A into plantar calluses of patients with PC results in improvement in the painful plantar 
keratoderma.
 She presented data from an ongoing study in her laboratory looking at 
single-nucleotide polymorphisms in keratins in dental enamel from teeth collected from 
patients with PC to investigate whether there is any relationship between PC and dental caries. 
10–13
 The speaker went on to describe and demonstrate a polyvinyl alcohol–starch 
film (Perspirograph) that was developed at TransDerm Inc., as an alternative to the traditional 
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starch–iodine test to detect and quantify small quantities of sweat, including from individual 
pores. 
Christopher Bunick (Yale University, New Haven, CT, U.S.A.) gave an update on his X-ray 
crystallography studies entitled ‘Defining the chemical and structural properties of human 
keratins using X-ray crystallography’. His work shows the importance of structural biology and 
how it can explain molecular mechanisms to help link genotype with the clinical phenotype of 
various keratin disorders, including PC.14
 
 Analyses performed to determine the most common 
chemical changes occurring in human skin disease mutations in keratins K1/K10, K5/K14, 
K6a, K6b, K6c, K16 and K17 identified substitution of one hydrophobic residue with another 
hydrophobic residue as the most common clinical change type, accounting for 20–28% of the 
mutations. 
Day 2 
The second day, chaired by Eli Sprecher, focused on treatment and proposed clinical trials. 
Discussions centred on clinical trial plans and on potential clinical end point measurements that 
would best evaluate these studies. Peter Hein (Grunenthal GmbH, Aachen, Germany) gave an 
insight into pain, and explained how the brain (as opposed to the body or organ) produces the 
pain. Pain is complex and multidimensional as it is a sensory experience/event, has a 
conscious/cognitive component, an emotional/affective component and a motivating 
component/dimension. He went on to discuss setting clinical end points for pain and different 
ways to measure pain objectively – ‘classical’ pain scales (typically unidimensional), pain 
measurement by tools and questionnaires, and multidimensional scales. He concluded that pain 
is what the patient feels and there are many factors that drive variability, which may obscure 
true treatment effects including effectiveness of intervention, site performance, treatment 
history and random variability. 
Michael Polydefkis (Johns Hopkins University, Baltimore, MD, U.S.A.) presented his recent 
findings ‘Quantitative analysis of cutaneous neuroanatomy in PC patients’ – a study comparing 
patterns of cutaneous innervation from affected and unaffected plantar skin biopsies from 
patients with PC and controls. The histological findings suggest that alterations in PC extend 
beyond keratinocytes, and may provide insights into the study of neuropathic pain in PC and 
potential therapeutic strategies.
Alain Hovnanian (Inserm UMR1163 and Imagine Institute, Paris, France) showed that the 
mammalian target of rapamycin pathway was activated in lesional skin from four patients with 
15
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Olmsted syndrome with mutations in TRPV3. He finished by reporting the results of using 
topical sirolimus for the treatment of one patient with a TRPV3 mutation. 
Edel O’Toole (Barts and The London School of Medicine and Dentistry, Queen Mary 
University of London, London) talked about the mechanism of action of oral retinoids and the 
advantages and disadvantages of different retinoids, including the newer retinoid, alitretinoin. 
She presented results from a study using Mattek epidermal three-dimensional cultures treated 
with acitretin or alitretinoin for 48 h. mRNA levels of the keratin genes involved in PC were 
measured to identify which were suppressed the most. She also discussed the revised plan for a 
clinical trial using oral retinoids. 
Details of another proposed clinical trial, botulinum toxin injections into plantar calluses, were 
presented by Ofir Arzi (Tel Aviv Sourasky Medical Center, Tel Aviv, Israel). As mentioned 
above, while not a cure, botulinum toxin A is being considered as a treatment to reduce the 
painful plantar keratoderma and improve the quality of life of patients with PC. Botulinum 
toxin A treatment is well tolerated and can last for several months. There followed a discussion 
on the trial plan itself and the end points to be used to evaluate the trial, which include a pain 
scale, a 6-min walk test, Patient-Reported Outcomes Measurement Information System, PC 
Quality of Life questionnaire, activity monitor, patient-reported weekly diaries and clinical 
photographs. 
The final two talks focused on nails. One of the distinguishing features of PC is variable 
hypertrophic nail dystrophy, ranging from just a few nails affected to involvement of all 20 
nails.1
Frances Smith presented findings of a small retrospective study, ‘Nail removal as a PC 
treatment’, using data collected by the IPCRR (DeKlotz et al., manuscript accepted for 
publication). The study looked at how many patients had chosen to have nails removed, at what 
age, their PC mutation and the procedure used. Patients completed an addendum questionnaire 
to answer questions including whether there was an overall positive outcome, any improvement 
in quality-of-life measures (pain, care, infections or appearance) and would they recommend 
nail removal to others. 
 This can be in the form of severely thickened nails or nails that terminate prematurely. 
Patients regularly file, grind or clip thickened nails. Campbell Stewart (Lake Washington 
Dermatology, Kirkland, WA, U.S.A.) shared the results of his study on ‘The histopathological 
features of the nail plate in PC’. Eighteen patients with genetically confirmed PC provided 56 
nail plate specimens that were processed and stained with haematoxylin and eosin and periodic 
acid–Schiff stain (manuscript in preparation). 
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This was followed by a discussion led by Albert Bravo (Pittsfield, MA, U.S.A.) and David 
Hansen (University of Utah, Salt Lake City, UT, U.S.A.) to determine the benefit of permanent 
destruction of selected nails and whether nail removal is an underutilized treatment option for 
PC. Overall, it was concluded that for some individuals permanent destruction of selected nails 
was beneficial, but that additional studies are needed to identify the procedure to achieve the 
best outcomes. 
 
Conclusions 
This year’s Annual Research Symposium of the IPCC revealed important progress in 
understanding PC pathophysiology and translation of research findings for the treatment of 
patients. Firstly, identifying that patients with PC experience neuropathic pain is a critical step 
for designing therapeutic approaches aimed at mitigating the debilitating pain that they 
experience. Secondly, extending the IPCRR and generating patient-based clinical data are 
invaluable tools to direct and prioritize future trials. Thirdly, developing tools that allow pain 
assessment, ambulation quantification and measurement of sweat production in patients with 
PC are not only necessary but will also be key to objective assessment of the clinical efficacy of 
potential therapeutics. All of these steps bring us a little closer to identifying efficient therapies 
for PC. The symposium ended with a reminder that the IPCRR data are ‘A treasure trove of 
information on PC’ and are readily available to IPCC members for studies and articles. 
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